ChromaDex Corporation has rebranded to Niagen Bioscience, Inc. with ticker symbol change to NAGE, accompanied by exceptional financial performance with operating income more than doubling.
The corporate rebrand suggests a strategic pivot to focus more heavily on their core Niagen (nicotinamide riboside) product line, potentially signaling management's confidence in this specific revenue stream. This represents a significant shift in corporate identity and market positioning that investors should monitor closely for execution risk and market reception.
The company delivered exceptional financial performance with operating income surging 111% to $16.3M and net income doubling to $17.4M, while gross profit grew a solid 35% to $83.2M. The balance sheet strengthened considerably with cash increasing 64% to $44.5M and stockholders' equity rising 66% to $76.5M, though total debt doubled to $5.0M. The 37% inventory reduction combined with strong revenue growth suggests improved operational efficiency and demand strength, making this a comprehensive positive financial picture that supports management's confidence in the rebrand.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Net income grew 103.3% — bottom-line growth signals improving overall business health.
Debt increased 100% — substantial leverage increase; assess whether deployed for growth or covering losses.
Equity base grew 66% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Cash position surged 63.6% — strong cash generation or capital raise providing significant financial cushion.
Asset base grew 55.8% — expansion through organic growth, acquisitions, or capital deployment.
Current assets grew 51% — improving short-term liquidity or inventory/receivables build.
Capex reduced 43.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Inventory drawn down 36.7% — strong sell-through or deliberate destocking; watch for supply constraints.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →